Statin therapy

DRUG9 trials

Sponsors

Baylor College of Medicine, Merck Sharp & Dohme LLC, Amarin Pharma Inc., The Alfred, Esperion Therapeutics, Inc.

Conditions

Acute Respiratory Distress SyndromeAtherosclerosisCardiovascular DiseasesCoronary Artery Disease (CAD)Drug AdherenceHeart FailureHypercholesterolemiaMigraine

Phase 2

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

CompletedNCT02072161

Esperion Therapeutics, Inc.Hypercholesterolemia

Start: 2014-03-31End: 2015-01-31Updated: 2019-03-29

Phase 3

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

CompletedNCT01492361

Amarin Pharma Inc.Cardiovascular Diseases

Start: 2011-11-30End: 2018-05-31Updated: 2022-04-14

Imaging of Coronary Plaques in Participants Treated With Evolocumab

CompletedNCT03570697

AmgenCoronary Artery Disease (CAD)

Start: 2018-11-19End: 2021-01-21Updated: 2022-05-03

Phase 4

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

CompletedNCT00687076

Baylor College of MedicinePeripheral Arterial Disease

Start: 2004-04-30End: 2010-12-31Updated: 2020-02-06

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

TerminatedNCT02114697

Emory UniversityAtherosclerosis

Start: 2014-04-30End: 2017-07-31Updated: 2018-09-11

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAcute Respiratory Distress Syndrome

Start: 2022-10-01End: 2023-12-31Target: 1000Updated: 2022-12-21

Unknown Phase

Study of Treatment Used for Migraine Headaches (MK-0974-076)

TerminatedNCT01421277

Merck Sharp & Dohme LLCMigraine

Start: 2011-05-19End: 2012-03-23Updated: 2017-06-20

Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study

CompletedNCT01554592

The AlfredHeart Failure

Start: 2012-03-31End: 2014-12-31Updated: 2016-06-01

Patient Autonomy and Statin Therapy Adherence

CompletedNCT05845580

Lithuanian University of Health SciencesDrug Adherence

Start: 2023-06-01End: 2024-08-01Updated: 2024-08-26

Related Papers

Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT

European Journal of Preventive Cardiology2025-09-201 citations

Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis

European Journal of Preventive Cardiology2025-04-083 citations

Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS

Atherosclerosis2025-02-214 citations

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Journal of the American Heart Association2025-02-198 citations

Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States

Journal of the American Heart Association2023-12-295 citations

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

European Heart Journal Open2023-11-0110 citations

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.

2023-03-06374 citations

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Journal of the American Heart Association2023-02-2125 citations

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Circulation2022-08-01117 citations

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Journal of the American College of Cardiology2022-04-2556 citations

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

Journal of the American Heart Association2022-04-0423 citations

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.

2022-03-16294 citations

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Journal of the American Heart Association2022-03-0937 citations

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Circulation2021-10-2865 citations

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Circulation2021-10-2855 citations

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Journal of the American College of Cardiology2021-10-0134 citations

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Cardiovascular Diagnosis and Therapy2021-02-0168 citations

Reduction in Revascularization With Icosapent Ethyl

Circulation2020-11-0555 citations

Circulation2019-11-11132 citations

Effects of Icosapent Ethyl on Total Ischemic Events

Journal of the American College of Cardiology2019-03-18247 citations

8 more papers not shown